AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug SubstanceAGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan.
AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare DiseasesCollaboration brings AGC Biologics’ advanced therapy expertise and global footprint to OTXL’s network, supporting a sustainable path from clinical development to commercial access for therapies serving the smallest patient populations
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug CandidateSuccessful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioprocessing and AGC Biologics' expanding global network
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality ComplianceGlobal CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories
